Posted On: 11/14/2016 6:51:32 PM
Post# of 1237
Main points from 2016 Q3 Report:
- No new convertible debt notes since March 30, 2016.
- No change to the share structure since May 11, 2016.
- On September 3, 2016, the Company entered into a Non-binding Letter of Intent to acquire all of the capital stock of a developer of hardware independent biometric processing software and leading provider of software development services as a subcontractor to major corporations. Under the terms of the Letter of Intent the definitive purchase agreement must close on or before December 15, 2016.
- Net sales increased from $180,000 to $226,561 - 26%.
- Operating expenses reduced from $888,295 to $554,220 - 38%.
- Other Income increased dramatically from $12,746 to $330,716.
- Net Loss decreased dramatically $716,413 to $17,605.
- No new convertible debt notes since March 30, 2016.
- No change to the share structure since May 11, 2016.
- On September 3, 2016, the Company entered into a Non-binding Letter of Intent to acquire all of the capital stock of a developer of hardware independent biometric processing software and leading provider of software development services as a subcontractor to major corporations. Under the terms of the Letter of Intent the definitive purchase agreement must close on or before December 15, 2016.
- Net sales increased from $180,000 to $226,561 - 26%.
- Operating expenses reduced from $888,295 to $554,220 - 38%.
- Other Income increased dramatically from $12,746 to $330,716.
- Net Loss decreased dramatically $716,413 to $17,605.
(0)
(0)
"Per Ardua Ad Astra" - "Through Adversity To The Stars"
A very apposite motto for those who trade successfully in the OTC market..
All posts are my opinion - trade at your own risk.
A very apposite motto for those who trade successfully in the OTC market..
All posts are my opinion - trade at your own risk.
